Free public records show GuangZhou Cellgenes Biotechnology Co., Ltd. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by GuangZhou Cellgenes Biotechnology Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
2 active studies led by GuangZhou Cellgenes Biotechnology Co., Ltd., of 4 in all
Source: ClinicalTrials.gov, Studies with GuangZhou Cellgenes Biotechnology Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies GuangZhou Cellgenes Biotechnology Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with GuangZhou Cellgenes Biotechnology Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show GuangZhou Cellgenes Biotechnology Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets GuangZhou Cellgenes Biotechnology Co., Ltd. is in.
Stories on the topics GuangZhou Cellgenes Biotechnology Co., Ltd. works in.
WHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Read
Every vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Read
The first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
ReadSearch all reports for GuangZhou Cellgenes Biotechnology Co., Ltd. All companies